Dr. Stephen Klassen and colleagues in their recent paper determined the effect of convalescent plasma therapy on mortality rate of patients with covid-19. They demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments. Their study recently appeared in Mayo Clinic Proceedings.
Convalescent plasma is a century-old passive antibody therapy that has been used to treat outbreaks of novel infectious diseases, including those affecting the respiratory system. At the onset of the pandemic, human convalescent plasma was used worldwide as it represented the only antibody-based therapy for coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Despite the emerging availability of monoclonal antibody therapies and vaccines for use in nonhospitalized patients through federal emergency authorization routes, convalescent plasma use has persisted (~100,000 units per month in the United States in early 2021) during subsequent waves of the COVID-19 pandemic because of surging hospitalizations and mortality rates. However, evidence for the efficacy of therapeutic COVID-19 convalescent plasma still requires definitive support from large randomized clinical trials (RCTs). As a result, there remains a lack of consensus on convalescent plasma use in hospitalized patients with COVID-19.
Now, Stephen Klassen and colleagues, by including 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies and 96 case reports or case series on pre-print servers or peer reviewed journals, investigated the impact of human convalescent plasma therapy on mortality of patients with covid-19.
(article continues below image)
They demonstrated that, the mortality rate of transfused patients with COVID-19 was lower than that of nontransfused patients with COVID-19 and suggested that early transfusion of high-titer plasma represents the optimal use scenario to reduce the risk of mortality among patients with COVID-19.
“Aggregation of mortality data from all controlled studies including RCTs and matched control studies indicated that patients transfused with convalescent plasma exhibited a 42% reduction in mortality rate compared with patients receiving standard treatment.”— told Stephen Klassen, first author of the study
These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agents in hospitalized patients with COVID-19.
Text credit: Our author/editor: S. Aman
Reference: Stephen A. Klassen, Jonathon W. Senefeld, Patrick W. Johnson, Rickey E. Carter, Chad C. Wiggins, Shmuel Shoham, Brenda J. Grossman, Jeffrey P. Henderson, James Musser, Eric Salazar, William R. Hartman, Nicole M. Bouvier, Sean T.H. Liu, Liise-anne Pirofski, Sarah E. Baker, Noud van Helmond, R. Scott Wright, DeLisa Fairweather, Katelyn A. Bruno, Zhen Wang, Nigel S. Paneth, Arturo Casadevall, Michael J. Joyner, The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis, Mayo Clinic Proceedings, Volume 96, Issue 5, 2021, Pages 1262-1275, ISSN 0025-6196, https://doi.org/10.1016/j.mayocp.2021.02.008. (https://www.sciencedirect.com/science/article/pii/S0025619621001403)
Note for editors of other websites: To reuse this article fully or partially kindly give credit either to our author S. Aman or provide a link of our article